Tamsulosin Hydrochloride
Product Images NDC 10544-550

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 10544-550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0.4mg 30ct (Label Tamsulosin HCl Caps 0.4mg Bpi(10544 550 30) Wockhardt(64679 516 30) Rev1)

Packaging label for Tamsulosin Hydrochloride Capsules, USP 0.4 mg, containing 30 capsules. The label includes the NDC number 10544-550-30 and manufacturer details for Blenheim Pharmacal, Inc. Instructions note storage at controlled room temperature and keeping the product in a light-resistant container. The label also specifies that the medication is for prescription only.*

FDA Label Image

Figure 1 (Tamsulosin HCl Capsules Figure 1)

A line graph comparing plasma concentration (ng/mL) over time (hours) for Tamsulosin Hydrochloride in fasted versus fed states. The graph shows two curves: a dashed line representing the fasted condition and a solid line representing the fed condition, indicating differences in drug plasma levels over a 36-hour period.*

FDA Label Image

Figure 2a (Tamsulosin HCl Capsules Figure 2a)

A line graph depicting mean change over duration of treatment in weeks. It compares three groups: 0.8 mg and 0.4 mg treatment doses, and a placebo group. The y-axis shows mean change, and the x-axis shows treatment duration from baseline through 13 weeks and LOCF. The 0.8 mg dose shows the greatest mean change, followed by 0.4 mg, with placebo showing the least change.*

FDA Label Image

Figure 2b (Tamsulosin HCl Capsules Figure 2b)

A line graph showing mean change over time in a treatment study of TAMSULOSIN HYDROCHLORIDE at doses of 0.3 mg and 0.4 mg compared to placebo. The x-axis represents duration of treatment in weeks, from 0 to about 13 weeks plus last observation carried forward (LOCF). The y-axis shows mean change, ranging from 0 to -11. Three lines depict treatment groups: 0.3 mg dose (circles), 0.4 mg dose (triangles), and placebo (squares). Mean change decreases more for the TAMSULOSIN groups than placebo over time.*

FDA Label Image

Figure 3a (Tamsulosin HCl Capsules Figure 3a)

A line chart showing mean change in a measured value (mL/sec) over a treatment duration of up to 13 weeks, including a last observation carried forward (LOCF) point. The graph compares three groups: 0.8 mg treatment, 0.4 mg treatment, and placebo, each represented by different symbols connected with dashed lines. Sample sizes at various time points are indicated along the x-axis.*

FDA Label Image

Figure 3b (Tamsulosin HCl Capsules Figure 3b)

A line graph depicting the mean change in mL/sec over the duration of treatment in weeks for TAMSULOSIN HYDROCHLORIDE 0.8 mg, 0.4 mg, and placebo groups. The x-axis shows treatment duration from 0 to 13 weeks plus LOCF, and the y-axis shows mean change from 0 to 3. Data points for the three groups are plotted with different markers and lines, showing changes at various intervals including week 1, 2, 5, 9, 13, and LOCF.*

FDA Label Image

Structure (Tamsulosin HCl Capsules Structure)

Chemical structure of Tamsulosin Hydrochloride showing its molecular components including methoxy, sulfonamide, and ethoxyphenyl groups along with the hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.